MRUS241220P65000
- 0.00
- 0.000.00%
Merus Newsroom
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Canaccord Genuity Sticks to Its Buy Rating for Merus (MRUS)
Merus Announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $73
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Announces Target Price $73
Promising Potential of Merus's Petosemtamab in HNSCC: A Buy Recommendation
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
A Quick Look at Today's Ratings for Merus(MRUS.US), With a Forecast Between $67 to $97
Merus Positioned for Growth Amid Promising Clinical Data and Resilience to Market Fluctuations
Merus Price Target Raised to $97.00/Share From $89.00 by Citigroup
Merus Is Maintained at Buy by Citigroup
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and C4 Therapeutics (CCCC)
Truist Financial Maintains Merus(MRUS.US) With Buy Rating
TD Cowen Maintains Merus(MRUS.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Arcellx Inc (ACLX)
Truist Financial Sticks to Its Buy Rating for Merus (MRUS)
Needham Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $85
Merus Price Target Maintained With a $85.00/Share by Needham
Merus's Promising Prospects: Buy Rating Highlighted by Positive Data on Peto's Efficacy in HNSCC
Reported Saturday, Merus Unveils Clinically Meaningful Activity For Petosemtamab In 2L+ R/M HNSCC And Expands Evaluation In MCRC